Corifollitropin Alfa
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Corifollitropin Alfa: From Controlled Ovarian Stimulation to Gastroduodenitis
One-Sentence Summary
Corifollitropin alfa is a long-acting FSH receptor agonist used clinically for controlled ovarian stimulation (COS) during IVF cycles. The TxGNN model's top prediction suggests possible efficacy for Gastroduodenitis, but this signal is supported by 0 clinical trials and 0 publications, and the drug is not currently marketed in Taiwan.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Controlled Ovarian Stimulation (COS) in IVF (inferred from rationale; not present in formal Taiwan license data — none exist) |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (marked as a High-severity data gap, DG002). Based on the repurposing rationale provided, corifollitropin alfa is a long-acting FSH receptor agonist acting on ovarian granulosa cells to promote follicular development, used for controlled ovarian stimulation in IVF.
There is no known biological pathway connecting FSH receptor signaling to gastroduodenitis (mucosal inflammation/injury). The model's own rationale explicitly states that the high TxGNN score likely reflects an indirect knowledge-graph path (e.g., shared comorbidity or protein nodes) rather than direct mechanistic evidence, and that no clinical trials or literature support this pairing. This prediction should therefore be treated as a hypothesis-generation signal only, not as mechanistically validated repurposing evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Corifollitropin alfa currently holds 0 licenses in Taiwan and is not marketed. No product, dosage form, or approved indication text is available for reference.
Safety Considerations
- Data Gap (Blocking): TFDA package insert warnings/contraindications are not currently available. This is flagged as a Blocking severity gap (DG001) — it prevents this candidate from entering the S1 safety pre-assessment stage.
- Drug Interactions: Query returned no results (not found in current DDI database).
Please refer to the official package insert for safety information once available; no substantive safety data currently exists in this evidence pack.
Other Predicted Indications (Same Drug)
This evidence pack included 7 additional TxGNN predictions for corifollitropin alfa, all similarly unsupported:
| Rank | Disease | Score | Evidence Level | Note |
|---|---|---|---|---|
| 2 | Migraine disorder | 99.63% | L5 | Only theoretical hormonal-withdrawal link; no direct study |
| 3 | Peptic ulcer disease | 99.61% | L5 | No known FSH-related mechanism |
| 4 | Migraine with brainstem aura | 99.59% | L5 | Mechanism mismatch (ion channel/brainstem pathology) |
| 5 | Raynaud disease | 99.59% | L5 | No vascular/FSH mechanistic overlap |
| 6 | Pulmonary hypertension | 99.44% | L5 | OHSS is an adverse effect, not therapeutic rationale |
| 7 | Kyphoscoliotic heart disease | 99.36% | L5 | Structural cardiopulmonary disorder, unrelated mechanism |
| 8 | Migraine susceptibility | 99.11% | L4 | 20 literature hits, all on epilepsy genetics/neuroinflammation — none about FSH or corifollitropin alfa |
All 8 predictions carry a Hold recommendation at decision stage S0.
Conclusion and Next Steps
Decision: Hold
Rationale: All predicted indications for corifollitropin alfa are supported only by TxGNN model scores (L5, or L4 with irrelevant literature) with zero clinical trials and no drug-specific publications. The drug is not marketed in Taiwan, and critical safety data (TFDA warnings/contraindications) is a Blocking data gap that prevents any S1 safety pre-assessment.
To proceed, the following is needed:
- Resolve DG001 (Blocking): retrieve TFDA/FDA/EMA package insert data for warnings and contraindications
- Resolve DG002 (High): obtain confirmed mechanism of action from DrugBank or primary literature
- Conduct a targeted literature search specifically linking FSH receptor signaling to gastroduodenitis (or any top-ranked candidate) before advancing beyond S0
- If no mechanistic or empirical support emerges, close out this candidate as knowledge-graph noise rather than a genuine repurposing signal
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.